EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range

Fabian Sattaf, Maike Scherf-Clavel, Stefan Unterecker, Andreas Eckert, Andreas Reif, Martina Hahn

Pharmacopsychiatry · 01.05.2025 · 58 (03) · 127-131

DOI: 10.1055/a-2511-3744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.05.2025. Verfasst von Fabian Sattaf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany. Hauptthemen laut MEDLINE: Drug Monitoring, Piperazines, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dose-related reference ranges can be used in therapeutic drug monitoring to monitor pharmacotherapy. The deviation of a measured serum concentration from the expected serum concentration at the corresponding dose can thus be identified early and responded to appropriately. The serum concentrations of patients treated with cariprazine regularly deviated from this dose-related reference range. As this is a relatively new drug with only one recommendation on values for a dose-related reference range, the values were tested for validity using real-world data. Serum concentrations of 24 patients receiving cariprazine once daily were analyzed retrospectively. Only patients without pharmacokinetic abnormalities were included. The measured serum concentrations were compared with the values of the dose-related reference range in the guidelines of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie consensus guidelines of 2017 and checked whether a sufficient number of serum concentrations were within the dose-related reference range. Only 45.8% of the measured serum concentrations were within the dose-related reference range. The C/D ratio was 1.58±0.73. Accordingly, a lower value of 0.85 and an upper value of 2.31 were calculated for the updated dose-related reference range, which is below the currently recommended values. The results suggest that the current values for the dose-related reference range are too high and require adjustment. The updated dose-related reference range lies between 0.85 and 2.31, with a mean of 1.58±0.73.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringPiperazinesAntipsychotic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultReference ValuesDose-Response Relationship, DrugAgedYoung Adult

Substanzen

cariprazinePiperazinesAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany.
  • Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.
  • Department of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt, Germany.

Zitieren

APA

Sattaf, F., Scherf-Clavel, M., Unterecker, S., Eckert, A., Reif, A., & Hahn, M. (2025). Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range. Pharmacopsychiatry, 58(03), 127-131. https://doi.org/10.1055/a-2511-3744

Vancouver

Sattaf F, Scherf-Clavel M, Unterecker S, Eckert A, Reif A, Hahn M. Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range. Pharmacopsychiatry. 2025;58(03):127-131. doi:10.1055/a-2511-3744

BibTeX
@article{Sattaf2025,
  author = {Sattaf, Fabian and Scherf-Clavel, Maike and Unterecker, Stefan and Eckert, Andreas and Reif, Andreas and Hahn, Martina},
  title = {Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range},
  journal = {Pharmacopsychiatry},
  year = {2025},
  volume = {58},
  number = {03},
  pages = {127--131},
  doi = {10.1055/a-2511-3744}
}
Kostenlos starten →